Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Ainara Soria et al.|The Lancet|2018Cited by 1.7k
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancerRicardo Hitt, Javier García, Juan J. Grau et al.|Annals of Oncology|2013Cited by 351
BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez‐Rodas, Stéphane Dalle, Caroline Dutriaux et al.|Journal of Clinical Oncology|2025Cited by 7